{"id":66946,"date":"2026-06-01T14:43:33","date_gmt":"2026-06-01T06:43:33","guid":{"rendered":"https:\/\/flcube.com\/?p=66946"},"modified":"2026-06-01T14:43:34","modified_gmt":"2026-06-01T06:43:34","slug":"true-health-medical-files-hong-kong-ipo-for-percutaneous-surgery-robot-portfolio-with-multiple-china-first-innovations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66946","title":{"rendered":"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Guangdong True Health Medical Technology Development Co., Ltd.<\/strong>, a leading Chinese developer of <strong>percutaneous puncture and ablation surgery robots<\/strong> founded in 2018, has submitted its <strong>initial public offering (IPO) prospectus<\/strong> to the <strong>Hong Kong Stock Exchange<\/strong>, planning to list on the bourse. The company has established a comprehensive <strong>intelligent medical robot product matrix<\/strong> centered on &#8220;<strong>percutaneous puncture, precision treatment<\/strong>,&#8221; featuring multiple <strong>China-first and global-first innovations<\/strong> across its surgical robotics and organ preservation platforms.<\/p>\n\n\n\n<h2 id=\"h-company-profile-amp-core-product-portfolio\" class=\"wp-block-heading\">Company Profile &amp; Core Product Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Guangdong True Health Medical Technology Development Co., Ltd.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2018<\/td><\/tr><tr><td><strong>IPO Status<\/strong><\/td><td>Prospectus filed with Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Core Focus<\/strong><\/td><td>Percutaneous puncture surgery and ablation surgery robots<\/td><\/tr><tr><td><strong>Strategic Theme<\/strong><\/td><td>&#8220;Percutaneous puncture, precision treatment&#8221;<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>China with global expansion potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-core-surgical-robot-platforms\" class=\"wp-block-heading\">Core Surgical Robot Platforms<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TH-S1<\/strong>: NMPA Class III approved for lung\/abdominal solid organ puncture; expanding to retroperitoneal lesions<\/li>\n\n\n\n<li><strong>TH-S<\/strong>: NMPA Class III approved for lung\/abdominal solid organ puncture<\/li>\n\n\n\n<li><strong>TH-S Pro<\/strong>: NMPA Class III approved for lung\/abdominal solid organ puncture<\/li>\n\n\n\n<li><strong>TH-SA<\/strong>: Registration application submitted May 2025 for lung\/abdominal solid organ puncture<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-milestones-amp-product-pipeline\" class=\"wp-block-heading\">Regulatory Milestones &amp; Product Pipeline<\/h2>\n\n\n\n<h3 id=\"h-approved-products\" class=\"wp-block-heading\">Approved Products<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TH-S1, TH-S, TH-S Pro<\/strong>: All hold <strong>Class III medical device registration certificates<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for percutaneous puncture surgeries of solid organs in lungs and abdomen<\/li>\n\n\n\n<li><strong>TH-X MW &amp; TH-X HMW<\/strong>: Percutaneous microwave ablation surgery robots approved for <strong>liver tumor treatment<\/strong><\/li>\n\n\n\n<li><strong>TH-P Series<\/strong>: Miniaturized percutaneous puncture surgery robot approved for <strong>lung and abdominal puncture procedures<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-development-pipeline\" class=\"wp-block-heading\">Development Pipeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MW150<\/strong>: Microwave ablation therapy instrument<\/li>\n\n\n\n<li><strong>TH-X Cryo<\/strong>: Cryoablation robot<\/li>\n\n\n\n<li><strong>THLS KI300 &amp; TH-LS LU100<\/strong>: Ex vivo organ preservation and evaluation systems<\/li>\n\n\n\n<li><strong>Dedicated Consumables<\/strong>: Full range compatible with surgical robots and organ preservation systems<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-positioning\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Positioning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">True Health operates in China&#8217;s rapidly expanding <strong>surgical robotics market<\/strong>, which is projected to reach <strong>\u00a520\u201325 billion ($2.8\u20133.5 billion) annually by 2028<\/strong>. The company&#8217;s focus on <strong>percutaneous procedures<\/strong> addresses a significant unmet need:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Minimally Invasive Advantage<\/strong>: Reduces patient recovery time, hospital stays, and complications compared to open surgery<\/li>\n\n\n\n<li><strong>Precision Enhancement<\/strong>: Robotic assistance improves accuracy in targeting small lesions and complex anatomical locations<\/li>\n\n\n\n<li><strong>Physician Training<\/strong>: Addresses shortage of highly skilled interventional radiologists through robotic assistance<\/li>\n\n\n\n<li><strong>Cost-Effectiveness<\/strong>: Lower capital expenditure compared to large surgical robot systems while maintaining clinical benefits<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This IPO represents a critical milestone in our mission to revolutionize minimally invasive surgery in China and globally,&#8221; said Dr. Chen Ming, Founder and Chief Executive Officer of True Health Medical. &#8220;Our comprehensive portfolio of percutaneous surgery robots, combined with our organ preservation systems, creates a unique integrated platform that addresses the full spectrum of precision intervention needs.&#8221;<\/p>\n\n\n\n<h2 id=\"h-competitive-differentiation\" class=\"wp-block-heading\">Competitive Differentiation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">True Health&#8217;s strategic advantages include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Leadership<\/strong>: Multiple <strong>Class III NMPA approvals<\/strong> in a highly regulated segment<\/li>\n\n\n\n<li><strong>Technology Integration<\/strong>: Seamless compatibility between robots, ablation systems, and consumables<\/li>\n\n\n\n<li><strong>Clinical Breadth<\/strong>: Coverage across <strong>puncture, microwave ablation, cryoablation, and organ preservation<\/strong><\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Continuous development of next-generation miniaturized and specialized platforms<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s <strong>TH-SA<\/strong> platform, pending regulatory approval, represents the next evolution in percutaneous robotics with enhanced capabilities for complex procedures.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view True Health as well-positioned to capture significant market share in China&#8217;s surgical robotics sector, with potential for international expansion leveraging its <strong>China-first innovations<\/strong> and cost-competitive manufacturing model.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding IPO plans, regulatory approvals, and market opportunities for True Health Medical. Actual results may vary based on Hong Kong Stock Exchange review, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26053100069_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26053100069_c.\"><\/object><a id=\"wp-block-file--media-aebc41f8-f8e0-40f2-90f1-77ffa5425198\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26053100069_c.pdf\">sehk26053100069_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26053100069_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-aebc41f8-f8e0-40f2-90f1-77ffa5425198\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66948,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,72,257],"class_list":["post-66946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-ipo","tag-true-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture and ablation surgery robots founded in 2018, has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, planning to list on the bourse. The company has established a comprehensive intelligent medical robot product matrix centered on &quot;percutaneous puncture, precision treatment,&quot; featuring multiple China-first and global-first innovations across its surgical robotics and organ preservation platforms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations\" \/>\n<meta property=\"og:description\" content=\"Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture and ablation surgery robots founded in 2018, has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, planning to list on the bourse. The company has established a comprehensive intelligent medical robot product matrix centered on &quot;percutaneous puncture, precision treatment,&quot; featuring multiple China-first and global-first innovations across its surgical robotics and organ preservation platforms.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T06:43:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T06:43:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations\",\"datePublished\":\"2026-06-01T06:43:33+00:00\",\"dateModified\":\"2026-06-01T06:43:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946\"},\"wordCount\":588,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0103.webp\",\"keywords\":[\"Cancer\",\"IPO\",\"True Health Medical Technology Development\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66946#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66946\",\"name\":\"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0103.webp\",\"datePublished\":\"2026-06-01T06:43:33+00:00\",\"dateModified\":\"2026-06-01T06:43:34+00:00\",\"description\":\"Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture and ablation surgery robots founded in 2018, has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, planning to list on the bourse. The company has established a comprehensive intelligent medical robot product matrix centered on \\\"percutaneous puncture, precision treatment,\\\" featuring multiple China-first and global-first innovations across its surgical robotics and organ preservation platforms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66946\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0103.webp\",\"width\":1080,\"height\":608,\"caption\":\"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations - Insight, China&#039;s Pharmaceutical Industry","description":"Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture and ablation surgery robots founded in 2018, has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, planning to list on the bourse. The company has established a comprehensive intelligent medical robot product matrix centered on \"percutaneous puncture, precision treatment,\" featuring multiple China-first and global-first innovations across its surgical robotics and organ preservation platforms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66946","og_locale":"en_US","og_type":"article","og_title":"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations","og_description":"Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture and ablation surgery robots founded in 2018, has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, planning to list on the bourse. The company has established a comprehensive intelligent medical robot product matrix centered on \"percutaneous puncture, precision treatment,\" featuring multiple China-first and global-first innovations across its surgical robotics and organ preservation platforms.","og_url":"https:\/\/flcube.com\/?p=66946","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T06:43:33+00:00","article_modified_time":"2026-06-01T06:43:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations","datePublished":"2026-06-01T06:43:33+00:00","dateModified":"2026-06-01T06:43:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66946"},"wordCount":588,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0103.webp","keywords":["Cancer","IPO","True Health Medical Technology Development"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66946#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66946","url":"https:\/\/flcube.com\/?p=66946","name":"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66946#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0103.webp","datePublished":"2026-06-01T06:43:33+00:00","dateModified":"2026-06-01T06:43:34+00:00","description":"Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture and ablation surgery robots founded in 2018, has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, planning to list on the bourse. The company has established a comprehensive intelligent medical robot product matrix centered on \"percutaneous puncture, precision treatment,\" featuring multiple China-first and global-first innovations across its surgical robotics and organ preservation platforms.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66946"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66946#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0103.webp","width":1080,"height":608,"caption":"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66946"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66946\/revisions"}],"predecessor-version":[{"id":66949,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66946\/revisions\/66949"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66948"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}